Logo

Clinical Data Closes $56M Genaissance Acquisition

Oct 07, 2005

NEW YORK, Oct. 7 (GenomeWeb News) - Clinical Data has closed its acquisition of Genaissance Pharmaceuticals, following approval by the companies' stockholders, Clinical said today.

 

Effective immediately, Genaissance will no longer trade on Nasdaq under the ticker symbol GNSC. Clinical Data's Nasdaq ticker symbol is CLDA. 

 

Clinical Data announced the $56 million all-stock acquisition in June. Genaissance will continue to market its DNA and pharmacogenomics services, the company said.

 

Clinical Data is still in the process of acquiring biomarker discovery firm Icoria, "which will add additional capabilities in the area of molecular diagnostics," according to a company statement today.

Breaking News
The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.